Selecting the Next Line of Therapy After SSA and PRRT in Progressive Pancreatic Neuroendocrine Tumor
This section focuses on the clinical decision making process following progression on lanreotide and lutetium Lu 177 dotatate. Dr Shaheen outlines how she approaches next line therapy selection in a ...
Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results